Articles

Sorafenib Active Third-Line in Refractory GIST

By Caroline Helwick

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Hypertension a Good Sign in Patients Receiving Sunitinib

Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Future of Colorectal Cancer Therapy: Novel Targeted Pathways

By Caroline Helwick

Colorectal Cancer, Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Competing Tests for Colorectal Cancer Risk Recurrence

By Caroline Helwick

Colorectal Cancer, Genitourinary Cancers Symposium

April 2011, Vol 2, No 2

Making Cancer Drugs Worth the Cost

By Christin Melton

HOPA Conference

April 2011, Vol 2, No 2

The Value of EHR Best Practices for Leading Oncology Networks

By Gerard M. Nussbaum; Laura K. Rehfeld

April 2011, Vol 2, No 2

Cancer Drugs and Life Expectancy Focus of Health Economist

Cancer Drugs, Personalized Medicine

April 2011, Vol 2, No 2

ODAC Supports Tightening Up Accelerated Approvals for New Cancer Drugs

By Daniel Denvir

Health Policy, Policies & Guidelines

April 2011, Vol 2, No 2

CMS’s Coverage Decision on Provenge: Implications for Payers

By Dalia Buffery, MA, ABD

Health Policy, Policies & Guidelines

April 2011, Vol 2, No 2

On March 30, 2011, the Centers for Medicare & Medicaid Services (CMS) announced its highly anticipated proposed national coverage decision concerning the prostate cancer immunotherapy sipuleucel-T (Provenge; Dendreon).

The Potential for Personalized Medicine to Improve the Value of Targeted Therapy

By Yu-Ning Wong, MD, MSCE

Economics & Value, Value-Based Care, VBCC Perspectives

April 2011, Vol 2, No 2

Page 316 of 329